Search

everythinglearnresearchcommunity

for

Search:↓

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

BM-PHA is as effective and safe as Restylane Perlane for improving nasolabial folds with minor side effects.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Oral Apremilast effectively treats alopecia areata in most patients.

Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

People with alopecia areata often have lower vitamin D levels than healthy people.

Rituximab can cause skin issues, but baricitinib may help improve them.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.

Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Baricitinib is effective and safe for treating severe alopecia areata.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.